Appotronics and Valeo announce strategic partnership for next-generation front lighting system

Valeo and Appotronics will collaborate to create new front lighting systems that utilize innovative laser video projection technology.

These innovative solutions will enhance adaptive lighting (ADB) functionalities in vehicles, significantly improving road safety and address drivers' increasing demands for more comfortable lighting options and entertainment features.

SHANGHAI, April 23, 2025 /PRNewswire/ -- Valeo, a world leader in automotive lighting systems and software, together with Appotronics (688007.SH), inventor of ALPD® laser display technology have announced a strategic partnership to offer a new generation of automotive front lighting solutions integrating exclusive Appotronics' ALL-in-ONE full-color laser headlight system.

Valeo will bring its unique expertise in lighting systems design and electronic control units design, along with unrivaled software capabilities, to integrate Appotronics recognized knowledge in projection systems design based on laser display technologies into new generation front lighting solutions.

Maurizio Martinelli, CEO of Valeo Light Division, stated: "This partnership strengthens Valeo's global leadership in next-generation lighting, combining safety, adaptability, and an enhanced driving experience. Leveraging our combined expertise in automotive lighting hardware and software, this new partnership reinforces existing technology alliances and reflects a shared ambition to redefine smart automotive lighting."

Yu Xin, Vice President of Appotronics, said: "The Appotronics-Valeo partnership represents a transformative step in smart automotive lighting, combining our complementary strengths to advance next-generation illumination solutions. Together, we're accelerating innovations that prioritize safety, intelligent adaptability, and personalized driving experiences for the global market."

A smart lighting system for safer and more immersive driving

By combining their expertise, Valeo and Appotronics will offer headlight solutions that provide advanced lighting functions (ADB) to complement traditional lighting functions (LH/HB), thereby improving safety and comfort for drivers and other road users.

Valeo will leverage its integration and software capabilities to integrate Appotronics state of the art ALPD® laser display technology. The front lighting system will offer high-definition information projection onto the ground, as well as outdoor movie projection capabilities—enabling video playback on flat surfaces or dedicated screens outside the vehicle.

ALL-in-ONE: A breakthrough in smart automotive lighting

The ALL-in-ONE system integrates several advanced functions in one compact module: Adaptive Driving Beam (ADB), road surface projection, and in-car cinema capabilities. Its smart system automatically optimizes lighting for different driving scenarios—extending illumination range with high beams on highways, and preventing glare with glare-free beams in urban areas. In addition, the headlight also offers 10-level brightness adjustment, complete with auto-focus, keystone correction, and image scaling capabilities.

The ALL-in-ONE headlight is powered by Appotronics' proprietary ALPD® semiconductor laser technology, which delivers 10 times the brightness of standard automotive LEDs with 200% greater luminous flux using equivalent DLP chips - all while consuming less energy.

About Valeo

Valeo is a technology company and partner to all automakers and new mobility players worldwide. Valeo innovates to make mobility safer, smarter and more sustainable. Valeo enjoys technological and industrial leadership in electrification, driving assistance systems, reinvention of the interior experience and lighting everywhere. These four areas, vital to the transformation of mobility, are the Group's growth drivers.

Valeo in figures:  21.5 billion euros in sales in 2024 | 106,100 employees, 28 countries, 155 plants, 64 research and development centers and 19 distribution platforms at February 28, 2025. Valeo is listed on the Paris Stock Exchange

Learn more at www.valeo.com 

Media Contact

Dora Khosrof | +33 7 61 52 82 75
Caroline De Gezelle | + 33 7 62 44 17 85
Jérôme Abribat | + 33 7 64 86 58 20
press-contact.mailbox@valeo.com

Investor Relations
+33 1 40 55 37 93
valeo.corporateaccess.mailbox@valeo.com

About Appotronics

Appotronics is the inventor of the ALPD® laser display technology and one of the first companies to list on the Shanghai Stock Exchange STAR Market. From optics for cinemas, vehicles and home, to AR glasses, Appotronics' cutting-edge products are designed to meet the evolving needs of consumers and businesses worldwide. Learn more at https://www.appotronics.com/

Media Contact

Song Jingli | +86 186 1017 6043
songjingli@highseador.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Appotronics and Valeo announce strategic partnership for next-generation front lighting system

Appotronics and Valeo announce strategic partnership for next-generation front lighting system

Appotronics and Valeo announce strategic partnership for next-generation front lighting system

AUCKLAND, New Zealand, May 2, 2025 /PRNewswire/ -- Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence.

There are now over 100 peer-reviewed studies describing the efficacy of the company's proprietary AROA ECM technology.

AROA's most recent publication was a large retrospective analysis of real-world evidence (RWE) from wound care centers in the US, assessing the efficacy of the company's Endoform Natural^TM product in treating venous leg ulcers (VLUs), in comparison to a leading reconstituted collagen dressing.

VLU's are open sores that are hard-to-heal because of impaired blood flow and can be very debilitating and painful.  These types of wounds are difficult for clinicians to treat successfully. For example, only ~40% of VLUs can be healed after 3 months of treatment and there is a relatively high chance that these wounds will recur^[1].

The peer-reviewed study, entitled "Clinical Efficacy of Ovine Forestomach Matrix and Collagen/Oxidized Regenerated Cellulose for the Treatment of Venous Leg Ulcers: A Retrospective Comparative Real-World Evidence Study" was published in the open access journal 'International Wound Journal in April 2025.

The study compared 470 VLU's that had been treated with Endoform Natural to 360 VLU's that had been treated with a reconstituted collagen product. The study used existing data from 223 wound care centers with minimal inclusion or exclusion criteria so that 'real-world' use of both products could be compared.

"There is a growing awareness of RWE studies to validate clinical performance" says Chief Scientific Officer, Dr. Barnaby May. "These types of studies enable much larger patient numbers to be compared versus traditional randomized controlled trials. Given that RWE studies use data from 'real-world' use of a treatment, the results can be more meaningful, especially in wound care where there is a high degree of variability in how wounds are cared for and patient factors."

The study found that VLUs treated with Endoform Natural healed up to ~ 8 weeks faster versus the comparator group, and the chances of the wound healing were significantly improved when Endoform Natural was used as part of treatment.

The striking difference in the healing outcomes demonstrate the potential for considerable cost reductions and improvements in patient quality of life, due to the significant improvements seen when VLUs were treated using Endoform Natural.

Dr. Gregory Bohn MD was part of the research team. "I was first introduced to Endoform in 2012 and started using the product to treat my own patients with VLUs. This new data validates what I have seen in my own practice managing VLUs with Endoform."

This is the second large retrospective RWE comparing Endoform Natural to a leading reconstituted collagen dressing. A previous study included the analysis of over 2,200 diabetic foot ulcers (DFUs) and also demonstrated significantly faster healing of DFUs using Endoform Natural^[2].

The study is available online here.

[1] Kolluri R, Lugli M, Villalba L, Varcoe R, Maleti O, Gallardo F, et al. An estimate of the economic burden of venous leg ulcers associated with deep venous disease. Vasc Med. 2022;27(1):63-72.

[2] Bosque BA, Frampton C, Chaffin AE, Bohn GA, Woo K, DeLeonardis C, Lepow BD, Melin MM, Madu T, Dowling SG, May BCH. Retrospective real-world comparative effectiveness of ovine forestomach matrix and collagen/ORC in the treatment of diabetic foot ulcers. Int Wound J. 2022 May;19(4):741-753.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.